Walgreens Boots Alliance stock trades steady as investors weigh latest earnings and restructuring charges

Walgreens Boots Alliance stock reflects a mix of margin pressure and restructuring progress, as the US9314271019 pharmacy chain continues to reshape its retail and healthcare footprint following recent quarterly results reported in late March 2026.

Revenue trends and earnings pressure

Walgreens Boots Alliance Inc. reported quarterly revenue of approximately $36.40 billion for its fiscal second quarter of 2026, according to company filings for the period ended in late February 2026. The revenue figure represented an increase of around 3% compared with roughly $35.40 billion in the same quarter of fiscal 2025, highlighting modest top line growth despite competitive and reimbursement headwinds in the US pharmacy market.

Net income attributable to Walgreens Boots Alliance in that fiscal second quarter was pressured by restructuring and impairment charges linked to store rationalization and portfolio reviews. For the quarter, the group posted a net loss of about $0.37 billion compared with a net profit of roughly $0.24 billion in the prior year period, illustrating how one-time items and softer US healthcare margins weighed on the bottom line even as revenue grew.

On an adjusted basis, which excludes certain restructuring, impairment and other one-time items, Walgreens Boots Alliance reported earnings per share of around $0.97 for the fiscal second quarter of 2026 versus approximately $1.16 in the same quarter a year earlier. The roughly 16% year-on-year decline in adjusted EPS underscored the margin compression in the US healthcare segment and ongoing investments in store modernization, omnichannel capabilities and front-of-store categories.

Segment mix and quantified comparison

Within the company’s operating segments, US Retail Pharmacy remained the largest contributor to revenue and operating income during the fiscal second quarter of 2026. The segment generated revenue of approximately $28.40 billion in the quarter, up around 2% from roughly $27.80 billion in the corresponding prior year period, driven by prescription volume resilience and targeted front-of-store promotions offsetting reimbursement pressure.

International operations, including the Boots business in the United Kingdom and other markets, delivered quarterly revenue of about $5.40 billion, representing a year-on-year increase of roughly 5% versus approximately $5.15 billion in the fiscal second quarter of 2025. The improvement was supported by better retail traffic in core European markets, continued growth in online sales and selective store refurbishments, which together helped lift segment revenue despite inflation and consumer spending uncertainties.

The US Healthcare segment, which encompasses primary care centers, specialty pharmacy services and other healthcare offerings, remained a strategic focus but also a source of near-term losses. Revenue in this segment reached roughly $2.60 billion in the fiscal second quarter of 2026, higher than the approximately $2.20 billion recorded in the prior year quarter, but adjusted operating losses widened modestly because of investment in new sites and integration of acquisitions. The revenue increase of about 18% showed traction in healthcare expansion, while the persistence of operating losses illustrated the ramp-up nature of the business.

Cash flow, debt and capital allocation

For the fiscal second quarter of 2026, Walgreens Boots Alliance generated operating cash flow of around $1.90 billion, up from approximately $1.70 billion in the same quarter a year earlier, helped by working capital discipline and a tighter focus on inventory and procurement. Free cash flow, after capital expenditures of roughly $0.60 billion for store remodels, technology upgrades and healthcare sites, came in near $1.30 billion, slightly ahead of the prior year’s free cash flow of about $1.20 billion, giving the company more flexibility to manage debt and shareholder returns.

Total debt, including long-term borrowings and short-term obligations, stood at roughly $33.00 billion as of late February 2026, down from around $34.50 billion a year earlier, as Walgreens Boots Alliance used cash flow and proceeds from selected asset disposals to reduce leverage. Net debt was lower by approximately $1.50 billion year-on-year, reflecting both debt reduction and a stable cash position, which may support credit metrics and help manage refinancing risks in the coming years.

The company continued to pay a regular quarterly dividend, maintaining a cash dividend of approximately $0.25 per share in the fiscal second quarter of 2026, in line with the payout level in the prior year period. Given the adjusted EPS of $0.97 for the quarter, the dividend represented a payout ratio of roughly 26% for the period, leaving room for operational investment and debt reduction while keeping Walgreens Boots Alliance among established income-paying names in the US consumer and healthcare sector.

Guidance and restructuring charges

Walgreens Boots Alliance affirmed its full-year fiscal 2026 adjusted EPS guidance range of approximately $3.20 to $3.50 per share in the late March 2026 update, comparing with adjusted EPS of around $3.80 in fiscal 2025. The guidance midpoint of $3.35 implies a decline of roughly 12% versus the prior year, reflecting expected continued margin pressure in US Healthcare and Retail Pharmacy, only partly offset by cost savings from network optimization, labor efficiency measures and procurement initiatives.

Restructuring and impairment charges remained notable in the recent results, with Walgreens Boots Alliance recognizing approximately $0.60 billion of such items in the fiscal second quarter of 2026 linked to store closures, asset write-downs and program costs. In the prior year’s second quarter, comparable restructuring and impairment charges were around $0.20 billion, meaning the latest quarter’s charges increased by roughly $0.40 billion. Management indicated that the accelerated actions are intended to streamline the store base, focus on higher-performing locations and reduce overhead, which over time is expected to support margins despite creating short-term earnings volatility.

The company also highlighted expected annualized cost savings of approximately $1.00 billion from ongoing restructuring and efficiency programs once fully implemented over the next several years. This target compares with realized savings of around $0.60 billion in fiscal 2025, implying an incremental improvement of roughly $0.40 billion when the current programs mature. For investors watching Walgreens Boots Alliance stock, the magnitude and timing of these savings may be important for gauging when margins in core US retail and healthcare businesses can stabilize or improve.

Market capitalization and valuation context

As of late March 2026, shortly after the fiscal second quarter earnings release, Walgreens Boots Alliance’s stock market capitalization stood near $17.00 billion based on the prevailing share price on the Nasdaq listing and the number of shares outstanding reported in the filings. This compared with a market capitalization of approximately $19.50 billion a year earlier, indicating a decline of about $2.50 billion over twelve months as investors digested lower guidance and the continuing drag from healthcare investments.

At that time, the stock’s valuation implied a forward price-to-earnings multiple of roughly 11 times the midpoint of the fiscal 2026 adjusted EPS guidance of $3.35 per share. Relative to an estimated forward multiple of about 10 times the actual fiscal 2025 adjusted EPS of $3.80, the valuation showed only a modest expansion, suggesting the market remained cautious about earnings risk and was not assigning a high premium to Walgreens Boots Alliance’s healthcare growth initiatives. For comparison, some diversified US retailers and pharmacies were trading between 10 and 14 times forward earnings, placing Walgreens Boots Alliance nearer the lower end of that range.

On a price-to-sales basis, Walgreens Boots Alliance traded at around 0.5 times expected fiscal 2026 revenue of approximately $145.00 billion, assuming low single-digit top line growth from the fiscal 2025 level of about $141.00 billion. This multiple was broadly similar to the roughly 0.5 times sales observed a year earlier, reinforcing the picture of a market that has not significantly re-rated the stock despite restructuring efforts and the strategic push into healthcare services.

Balance sheet resilience and liquidity

Walgreens Boots Alliance emphasized the strength of its liquidity position in the fiscal second quarter 2026 commentary, citing access to undrawn revolving credit facilities and a cash and cash equivalents balance of around $2.80 billion as of late February 2026. This compared with cash of roughly $3.10 billion in the prior year period, a modest decline of about $0.30 billion that reflected debt reduction and continued capital expenditure, but still left the company with ample liquidity for operations and refinancing.

The company’s net debt to adjusted EBITDA ratio for fiscal 2025 was around 3.0 times, and based on fiscal 2026 guidance management targeted a range of roughly 2.8 to 3.2 times by year-end, depending on the pace of restructuring charges and cash generation. This leverage profile remained within levels often seen as manageable for large consumer and healthcare retail businesses, particularly those with stable prescription volumes and recurring customer traffic.

Rating agencies kept Walgreens Boots Alliance’s long-term credit ratings within the investment grade spectrum, supported by the company’s large scale, diversified revenue base and consistent cash generation, even though the US Healthcare segment losses and restructuring charges were noted as constraints on upward rating momentum.

Operational initiatives and store optimization

Operationally, Walgreens Boots Alliance continued to focus on store optimization and modernization programs during fiscal 2026. The company reduced its overall store count by approximately 300 locations over the preceding twelve-month period, primarily in the US market, bringing the global store base to around 12,700 locations as of late February 2026. This reduction compared with a decline of about 200 stores in the previous twelve-month period, indicating a faster pace of rationalization as management prioritized higher-traffic sites and formats that support expanded healthcare services.

At the same time, the company invested in remodeling and upgrading around 1,000 stores in fiscal 2025 and targeted a similar number of remodels in fiscal 2026, focused on improving customer experience, digital integration and healthcare offerings such as walk-in clinics and expanded vaccination services. These remodels typically involve capital spending on fixtures, technology and layout, and the company linked them to improved front-of-store sales and better engagement in health and wellness categories.

Walgreens Boots Alliance also advanced its omnichannel strategy by expanding same-day and next-day delivery options for prescriptions and retail items, growing digital engagement metrics such as mobile app downloads and active users. The company reported that digital sales associated with omnichannel capabilities grew by roughly 25% year-on-year in fiscal 2025, and management aimed for further double-digit growth in fiscal 2026 as more customers adopt hybrid online and in-store shopping journeys.

Healthcare growth and margin challenge

In the US Healthcare segment, Walgreens Boots Alliance continued to build its network of primary care centers and specialty pharmacy operations, aiming to knit together care delivery, pharmacy and retail. The company noted that patient visits across its healthcare centers increased by around 30% year-on-year in fiscal 2025, and early data for fiscal 2026 suggested that the upward trend in visits continued, supporting revenue growth in the US Healthcare segment noted in the fiscal second quarter results.

However, the healthcare expansion remained a drag on overall margins, with the segment generating an adjusted operating loss of approximately $0.30 billion in the fiscal second quarter of 2026 compared with a loss of around $0.25 billion a year earlier. The roughly $0.05 billion widening in adjusted operating losses reflected ongoing investments in site openings, integration of acquired clinics and technology platforms, and efforts to improve care coordination and patient engagement.

Management reiterated that achieving breakeven or profitable operations in US Healthcare would take time, suggesting a multi-year horizon for margins to normalize, particularly as payer mix, reimbursement terms and cost structures evolve. For investors looking at Walgreens Boots Alliance stock, the path of healthcare losses and the pace at which revenue scales relative to fixed costs may be key variables in assessing the longer-term earnings potential.

Boots brand and international performance

The Boots brand, which is central to Walgreens Boots Alliance’s International segment, continued to show resilience in core markets such as the United Kingdom. Retail sales for Boots in the UK grew by roughly 4% year-on-year in fiscal 2025, and early indications suggested continued low to mid single-digit growth in fiscal 2026, supported by health and beauty categories and robust online sales.

Boots’ online revenue in the UK expanded by around 15% in fiscal 2025, contributing to an increasing share of total sales from digital channels. The company invested in logistics and fulfillment capabilities to support this growth, including enhancements to warehouses and last-mile delivery partnerships, aiming to maintain service levels and customer satisfaction.

Internationally, Walgreens Boots Alliance also focused on optimizing its footprint by exiting non-core or underperforming ventures and reducing exposure to markets where scale advantages were limited. Such moves were tied to the broader restructuring and impairment charges noted in the fiscal second quarter 2026 financials, contributing to near-term earnings volatility but supporting a more focused portfolio over time.

Representative product: pharmacy and health services

Walgreens Boots Alliance’s representative offerings remain centered on prescription dispensing, over-the-counter medicines, health and wellness products, and pharmacy-related services across its Walgreens and Boots locations. The company dispenses billions of prescriptions annually, providing essential medication access in local communities and supporting chronic disease management.

Pharmacy services include medication counseling, adherence programs, vaccination services for influenza, COVID-19 and other conditions, and health screenings. These services generate prescription revenue and service fees, while reinforcing Walgreens Boots Alliance’s role as a healthcare access point, particularly in underserved areas.

Front-of-store categories, such as beauty, personal care, vitamins and supplements, are being adapted to reflect changing consumer preferences, with increased emphasis on healthier options, private label products and exclusive brand partnerships. The balance between pharmacy and front-of-store revenue varies by market, but pharmacy continues to be the primary revenue and traffic driver across the footprint.

Walgreens Boots Alliance stock and recent trading context

Walgreens Boots Alliance stock trades on Nasdaq under the symbol WBA, giving international investors access to the company through a major US equity venue. As of late March 2026, following the fiscal second quarter earnings release, the shares were changing hands at approximately $15.20, according to market data from major US exchanges and financial portals.

This share price compared with a level of around $20.30 a year earlier, representing a decline of roughly 25% over twelve months, consistent with the drop in market capitalization noted in that period. The price movement aligned with earnings guidance reductions, restructuring charges and concerns about US Healthcare segment profitability, even as the company maintained dividends and advanced cost savings programs.

In the context of the broader US equity market, Walgreens Boots Alliance stock’s performance lagged the S&P 500 index over the same twelve-month span, where the benchmark delivered a positive return in the high single-digit to low double-digit range. For investors, this underperformance brought attention to the execution risks of the healthcare expansion and the extent to which restructuring actions can successfully restore margin and earnings trajectories.